Lumacaftor for improved brain blood flow in heart failure
Part of Mental health clinical trials.
This trial tests if lumacaftor, a medication used in cystic fibrosis, can improve blood flow to the brain in people with stable heart failure. It might help if you have heart failure with reduced pumping function and low brain blood flow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with stable heart failure (NYHA class II-III) and a low ejection fraction (under 40%).
- You must have low blood flow to the brain (measured as 45 or less on a special scan).
- You cannot have had a hospital stay for heart failure in the last 3 months.
- You must not have cystic fibrosis or take certain medications (like antiallergics, antibiotics, or antidepressants).
- You must be able to have an MRI without sedation and not have a non-MRI compatible device or clip.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This trial compares two ways of giving Lumason (an ultrasound contrast agent) to improve images of the left ventricle in people whose initial heart ultrasound was unclear. It may help those with a 'suboptimal' view of the heart's pumping chamber.
This trial tests a new medicine called CDR132L to see if it improves heart structure and function in people with heart failure who have a thickened heart muscle and reduced pumping ability. Participants will be randomly assigned to receive either the study drug or a placebo.
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.